Welcome to our dedicated page for dnay news (Ticker: dnay), a resource for investors and traders seeking the latest updates and insights on dnay stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect dnay's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of dnay's position in the market.
Telesis Bio reported record revenue of $9 million for 4QFY22, reflecting a 191% increase from 4QFY21. The BioXp® revenue rose by 131% to $3 million in the same quarter. The company achieved its first technical milestone with Pfizer, enhancing its SOLA technology for DNA synthesis. Gross margin is expected to exceed 60%, while operating expenses rose to $14-15 million compared to $13 million last year. As of December 31, 2022, Telesis Bio holds $41 million in cash.
Telesis Bio reported a record revenue of $6.7 million for 3QFY22, marking a 140% increase compared to $2.8 million in 3Q FY2021. The company’s BioXp® Kit revenue rose by 69% to $884,000 over the same period. Telesis Bio increased its full-year revenue guidance to between $23 million and $25 million for fiscal 2022. The company aims to lead in benchtop automation for synthetic biology and plans to introduce new BioXp® kits starting Q1 2023 to enhance customer offerings.
Telesis Bio (Nasdaq: DNAY) announced it will release its third quarter 2022 financial results on November 8, 2022, after market close. A conference call will follow at 1:30 p.m. PT, where management will discuss the results and corporate highlights. Interested parties can access the press release and live audio webcast on the company’s website, with replay available for 30 days. Telesis Bio focuses on synthetic biology solutions, enabling rapid DNA and RNA synthesis through its innovative BioXp system.
Telesis Bio (Nasdaq: DNAY) has announced a collaboration with Cellibre to streamline production of CRISPR-Cas9 guide RNA. This partnership aims to optimize the BioXp® Digital-to-Biological Converter™ (DBC) for automated manufacturing of guide RNA, addressing challenges related to the rapid production of high-quality gRNA. The BioXp® DBC will integrate Telesis Bio’s enzymatic DNA synthesis technology, enabling same-day RNA design and build capabilities. This collaboration is expected to enhance workflows in cell engineering and accelerate natural product production.
Codex DNA, Inc. (Nasdaq: DNAY) announced a name change to Telesis Bio on October 12, 2022, reflecting its expanded capabilities in synthetic biology and genomics. CEO Todd Nelson highlighted the company's innovative spirit and versatile technologies, including the BioXp® automation platform and Gibson Assembly® method. Although the name change signifies growth, there will be no changes to corporate structure or financial reporting. This rebranding aims to align with the company’s strategic vision and focus.
Codex DNA (NASDAQ: DNAY) recently announced the release of BioXp® Error Corrected Libraries which offer a two-fold increase in sequence fidelity. This advancement allows researchers to automate the synthesis of DNA variant libraries using the BioXp® workstation, enabling up to 64 million variants per well. The new technology enhances applications in antibody therapeutics, enzyme engineering, and precision medicine. It enhances workflow efficiency and accuracy, aiming to expedite research in synthetic biology.
Codex DNA announces the nomination of its BioXp™ 9600 system for the prestigious World of Laboratory Tech Award. This automated benchtop instrument enhances synthetic biology workflows by enabling overnight DNA and mRNA synthesis, overcoming limitations of traditional methods. Showcased at the World of Technology & Science conference in Utrecht on Sept. 27, 2022, the system offers increased throughput and productivity, allowing scientists to efficiently integrate design and build cycles. Codex DNA aims to empower scientific advancements in biologics and vaccine development through this innovative platform.
Codex DNA, Inc. (NASDAQ: DNAY) announced the commercial release of its BioXp™ 9600 system, a fully automated high-throughput platform for synthetic biology, aimed at accelerating vaccine and biologic discovery. This system automates the synthesis of genes and mRNA, significantly reducing research turnaround times. The release occurred one quarter ahead of schedule, underlining the company's commitment to innovation. Codex DNA plans to introduce additional BioXp kits in Q1 2023, enhancing the system's functionality and flexibility for scientists.
Codex DNA, Inc. (DNAY) reported a strong second quarter 2022, with revenue reaching $5.7 million, a 98% increase from $2.9 million in Q2 2021. Organic revenue growth was 44% year-over-year, excluding Eton Bioscience contributions. Key highlights include a 66% rise in BioXp kit revenue and a gross margin increase to 48%. However, the net loss widened to $14.8 million. The company raised its full-year revenue guidance to between $22 million and $24 million, up from $19 million to $21 million.
Codex DNA (Nasdaq: DNAY) will release its second quarter 2022 financial results on August 9, 2022, post-market. A conference call is set for the same day at 1:30 p.m. Pacific Time to discuss results and corporate highlights.
Investors can access the press release and live audio webcast on the company's website. Codex DNA is known for its innovative synthetic biology solutions, including the industry-standard Gibson Assembly® method and the BioXp™ system that accelerates DNA/RNA synthesis.
FAQ
What is the market cap of dnay (dnay)?
